Detalles de la búsqueda
1.
Clinical Results and Biomarker Analyses of Axitinib and TRC105 versus Axitinib Alone in Patients with Advanced or Metastatic Renal Cell Carcinoma (TRAXAR).
Oncologist
; 26(7): 560-e1103, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-33829609
2.
A phase 1, open-label, dose-escalation study of BIIB022 (anti-IGF-1R monoclonal antibody) in subjects with relapsed or refractory solid tumors.
Invest New Drugs
; 32(3): 518-25, 2014 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-24458261
3.
Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase 2 trial.
Blood Cancer J
; 12(1): 9, 2022 01 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-35075109
4.
Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma.
J Clin Oncol
; 39(22): 2430-2442, 2021 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34111952
5.
Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations.
Lancet Haematol
; 6(7): e366-e374, 2019 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-31109827
6.
Weight-based dosing of Yttrium 90 ibritumomab tiuxetan in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
Clin Lymphoma Myeloma
; 7(8): 514-7, 2007 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-18021468
7.
Treatment with yttrium 90 ibritumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin's lymphoma.
Leuk Lymphoma
; 47(4): 629-36, 2006 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-16690521
8.
The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis.
J Am Acad Dermatol
; 54(1): 61-3, 2006 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-16384756
9.
An integrated analysis of thirteen trials summarizing the long-term safety of alefacept in psoriasis patients who have received up to nine courses of therapy.
Clin Ther
; 27(12): 1912-21, 2005 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-16507377
10.
Safety and efficacy of alefacept in elderly patients and other special populations.
J Drugs Dermatol
; 4(6): 718-24, 2005.
Artículo
en Inglés
| MEDLINE | ID: mdl-16302557
11.
Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma.
Clin Lymphoma
; 5(2): 98-101, 2004 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-15453924
12.
Treatment-related myelodysplastic syndrome and acute myelogenous leukemia in patients treated with ibritumomab tiuxetan radioimmunotherapy.
J Clin Oncol
; 25(27): 4285-92, 2007 Sep 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-17709799
13.
Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan.
Cancer
; 109(9): 1804-10, 2007 May 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-17380530
14.
Epidemiology of reproductive and hormonal factors in thyroid cancer: evidence from a case-control study in the Middle East.
Int J Cancer
; 97(1): 82-9, 2002 Jan 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-11774247
15.
Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study.
Blood
; 103(12): 4429-31, 2004 Jun 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-15016644
Resultados
1 -
15
de 15
1
Próxima >
>>